UBS Group
LYEL icon

UBS Group’s Lyell Immunopharma LYEL Stock Holding History

UBS Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$638K Buy
31,814
+18,611
+141% +$435K ﹤0.01% 5897
2025
Q4 		$406K Sell
13,203
-8,039
-38% -$180K ﹤0.01% 6203
2025
Q3 		$345K Sell
21,242
-4,392
-17% -$50.2K ﹤0.01% 6347
2025
Q2 		$227K Buy
25,634
+20,114
+364% +$183K ﹤0.01% 6638
2025
Q1 		$59.4K Sell
5,520
-37,694
-87% -$462K ﹤0.01% 7448
2024
Q4 		$553K Buy
43,214
+37,778
+695% +$749K ﹤0.01% 5770
2024
Q3 		$150K Buy
5,436
+1,195
+28% +$35.1K ﹤0.01% 6071
2024
Q2 		$123K Sell
4,241
-5,718
-57% -$272K ﹤0.01% 6033
2024
Q1 		$444K Sell
9,959
-983
-9% -$42.1K ﹤0.01% 5291
2023
Q4 		$425K Buy
10,942
+1,188
+12% +$42.8K ﹤0.01% 5227
2023
Q3 		$287K Buy
9,754
+2,095
+27% +$99.5K ﹤0.01% 5089
2023
Q2 		$487K Sell
7,659
-3,405
-31% -$188K ﹤0.01% 4847
2023
Q1 		$522K Sell
11,064
-9,487
-46% -$507K ﹤0.01% 4652
2022
Q4 		$1.43M Buy
20,551
+19,535
+1,923% +$1.94M ﹤0.01% 3729
2022
Q3 		$149K Buy
1,016
+755
+289% +$102K ﹤0.01% 5361
2022
Q2 		$34K Buy
261
+11
+4% +$1.12K ﹤0.01% 6264
2022
Q1 		$25K Sell
250
-470
-65% -$56.9K ﹤0.01% 7194
2021
Q4 		$112K Buy
720
+707
+5,438% +$158K ﹤0.01% 6213
2021
Q3 		$4K Buy
+13
New +$3.9K ﹤0.01% 8652

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group's LYEL Position: Q1 2026 in Review

UBS Group increased its Lyell Immunopharma (LYEL) stake by 141% in Q1 2026, buying an estimated $435K and bringing the position to 31,814 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #5897.

UBS Group first reported a position in LYEL in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.43M in Q4 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • UBS Group held 31,814 shares of Lyell Immunopharma worth $638K as of Q1 2026.
  • UBS Group bought 18,611 Lyell Immunopharma shares in Q1 2026, an estimated $435K.
  • Lyell Immunopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5897 holding.
  • UBS Group first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 19 quarters since.
  • UBS Group's Lyell Immunopharma position peaked at $1.43M in Q4 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.